Supplemental Materials of FY9/22 Consolidated Financial Results

November 10 , 2022

Fuji Pharma Co., Ltd.





Summary of FY9/22 Consolidated Financial Results

		reference						
	FY9/21	FY9/21	FY9/22	YoY Ch		FY9/22 Forecast	vs Fcst	
(¥million)	Full Year	Full Year	Full Year Full Year		(Old accounting standards)			
	Old accounting standards	New accounting standards	New accounting standards	Amount	Ratio	New accounting standards	Progress Ratio	
Net Sales	33,990	32,645	35,426	1,436	4.2%	35,966	98.5%	
Gross Profit	14,751	13,406	14,558	▲ 193	-1.3%	-	-	
Gross Margin	43.4%	41.1%	41.1%	-	-	-	-	
SG&A Expenses	11,402	10,056	10,781	▲ 621	-5.4%	-	-	
SG&A Margin	33.5%	30.8%	30.4%	-	-	-	-	
Operating Profit	3,349	3,349	3,777	428	12.8%	3,490	108.2%	
Operating Margin	9.9%	10.3%	10.7%	-	-	9.7%	-	
Ordinary Profit	3,250	3,250	3,725	475	14.6%	3,540	105.2%	
Ordinary Margin	9.6%	10.0%	10.5%	-	-	9.8%	-	
Profit Attributable to Owners of Parent	2,432	2,432	2,696	264	10.9%	2,562	105.2%	
Profit Margin	7.2%	7.4%	7.6%	-	-	7.1%	-	
EBITDA ^{*1}	5,243	5,243	6,252	1,009	19.2%	5,250	119.1%	
EBITDAR ^{*2}	7,689	7,689	8,738	1,049	13.6%	8,059	108.4%	
Capital Expenditure	3,392	3,392	7,150	3,758	110.8%	7,172	99.7%	
Depretiation (Including Leased Equipment)	1,893	1,893	2,475	582	30.7%	1,760	140.6%	
R&D Expenses	2,446	2,446	2,485	39	1.6%	2,809	88.5%	
R&D Expenses Ratio	7.2%	7.5%	7.0%	-	-	7.8%	-	

*1) EBITDA : Gross Profit – SG&A Expenses + Depretiation (Including Leased Equipment)

*2) EBITDAR : Gross Profit-SG&A Expenses+Depretiation (Including Leased Equipment)+R&D Expenses

* From the beginning of FY9/22, to apply "The Accounting Standards for Recognizing Revenues" (corporate accounting standard No. 29), the abovementioned FY9/22 consolidated financial results and consolidated forecast is the figure after the application of new accounting standards.




Sales by Therapeutic Category

	FY9/18	FY9/19	FY9/20	FY9/21	FY9/22	YoY Cl	nange
(¥million)	Old accounting standards	Old accounting standards	Old accounting standards	Old accounting standards	New accounting standards	Amount	Ratio
Hormone drugs	10,981	10,741	10,363	11,758	13,301	1,543	13.1%
Diagnostic drugs	14,323	10,827	8,570	8,310	7,447	▲ 863	-10.4%
Metabolic drugs	2,882	3,074	3,216	2,917	2,318	▲ 599	-20.5%
Cellular function affecting drugs	881	932	966	1,002	948	▲ 54	-5.4%
Nervous system & sensory organs drugs	165	1,099	1,200	1,170	924	▲ 246	-21.0%
Vitamin drugs	391	407	379	401	868	467	116.5%
Antibiotics & Chemotherapeutics	801	820	689	595	651	56	9.4%
Dermatological drugs	505	537	538	558	601	43	7.7%
Others	4,500	5,298	5,335	5,144	5,498	354	6.9%
Of which, CMO Business (FUJI)	1,471	2,303	2,798	3,146	3,622	476	15.1%
CMO Business (OLIC)	2,476	2,539	2,532	2,131	2,866	735	34.5%
Total	37,909	36,279	33,793	33,990	35,426	1,436	4.2%

*CMO Business (OLIC) is the amount after consolidation adjustment

Sales Breakdown by Therapeutic Category





©2022 Fuji Pharma Co., Ltd. All rights reserved.

From the beginning of FY9/22, to apply "The Accounting Standards for Recognizing Revenues" (corporate accounting standard No. 29), the above-mentioned FY9/22 sales by therapeutic category is the figure after the application of new accounting standards. Therefore, YoY changes(in amount and ratio) are for reference only.

Sales of Top 15 Products

Product Name	Therapeutic	FY9/18	FY9/19	FY9/20	FY9/21	FY9/22	YoY Ch	nange	FY9/22
(¥million)	Category	Old accounting standards	Old accounting standards	Old accounting standards	Old accounting standards	New accounting standards	Amount	Ratio	Budget
★IOPAMIDOL injection	Diagnostic drugs	6,769	7,192	6,401	6,224	5,996	▲ 228	-3.7%	5,829
★IOHEXOL injection	Diagnostic drugs	2,010	2,287	2,172	2,088	1,707	▲ 381	-18.2%	1,703
Favoir [®] tablets	Hormone drugs	552	768	1,019	1,331	1,663	332	24.9%	1,541
DIENOGEST tablets	Hormone drugs	828	1,136	1,311	1,734	1,652	▲ 82	-4.7%	1,741
Filgrastim BS Injection Syringe	Metabolic drugs	<u>1,721</u>	<u>1,974</u>	<u>2,299</u>	<u>2,069</u>	<u>1,492</u>	▲ 577	<u>-27.8%</u>	<u>1,784</u>
◆UTROGESTAN [®] vaginal capsules	Hormone drugs	<u>649</u>	<u>788</u>	<u>712</u>	<u>889</u>	<u>1,218</u>	<u>329</u>	<u>37.1%</u>	<u>1,093</u>
LEVONORGESTREL tablets	Hormone drugs	-	431	660	847	1,062	215	25.4%	857
Labellefille [®] tablets	Hormone drugs	526	709	862	1,002	960	▲ 42	-4.2%	1,294
LUNABELL [®] tablets (LD/ULD)	Hormone drugs	<u>2,769</u>	<u>1,583</u>	<u>1,045</u>	<u>978</u>	<u>955</u>	▲ 23	-2.4%	<u>767</u>
GABAPEN [®] Tablets/Syrup	<u>Nervous system & sensory</u> organs drugs	-	<u>943</u>	<u>1,104</u>	<u>1,092</u>	<u>885</u>	▲ 207	<u>-19.0%</u>	<u>1,107</u>
DEXART [®] injection	Hormone drugs	870	894	874	961	865	▲ 96	-10.0%	898
◆HMG injection	Hormone drugs	880	811	752	883	736	▲ 147	-16.6%	675
F-meno [®] capsules	Hormone drugs	<u>_</u>	±	<u>_</u>	Ξ	<u>681</u>	<u>-</u>	=	<u>_</u>
◆BUSERELIN nasal solution	Hormone drugs	443	441	402	460	582	122	26.4%	457
◆FOLYRMON [®] -P injections	Hormone drugs	638	632	560	408	484	76	18.5%	633
Total Top 15 Sales		18,661	20,597	19,468	20,971	20,945	▲ 26	-0.1%	-
Pct. Of Total Sale	es	49.2%	56.8%	57.6%	61.7%	59.1%			-
Other Products		16,771	13,142	11,792	10,887	11,614	727	6.7%	-
CMO Business (OLIC)		2,476	2,539	2,532	2,131	2,866	735	34.5%	2,457
Total		37,909	36,279	33,793	33,990	35,426	1,436	4.2%	35,966
[Reference]Branded contrast media		5,288	1,255	0	0	0			

Acute Medical Care Women's Healthcare

*Product name change : IOPAMIDOL injection (Former name : OYPALOMIN[®] injection), IOHEXOL injection (Former name : IOPAQUE[®] injection)

◆Infertility Treatment drugs

* Underlined products are the Fuji Pharma branded drugs (branded drugs branded generic drugs (transferred products) and biosimilars)

* CMO Business (OLIC) is the amount after consolidation adjustment

From the beginning of FY9/22, to apply "The Accounting Standards for Recognizing Revenues" (corporate accounting standard No. 29), the abovementioned FY9/22 sales of Top 15 products and FY9/22 Budget are the figure after the application of new accounting standards. Therefore, YoY changes(in amount and ratio) are for reference only.



Note on forecast and prospects

The financial forecasts and other projections provided in this presentation are based on information available at the time of its compilation and it therefore contains an element of uncertainty and potential risks.

Actual results may differ significantly from these forecasts for a number of reasons.

It should also be noted that the views and/or facts presented here may be altered or deleted without prior notification.

Information in this presentation about pharmaceuticals (including items in the pipeline) is not provided for the purpose of marketing or advertising or of supplying medical advice.

Contact Information

Fuji Pharma Co., Ltd. Corporate Planning Section Corporate Planning Department Corporate Strategy Division

- **E-Mail** : fsk_ir@fujipharma.jp
- **U R L** : https://www.fujipharma.jp/



©2022 Fuji Pharma Co., Ltd. All rights reserved.